Citius Oncology, Inc. (CTOR) Revenue History
Annual and quarterly revenue from 2022 to present
CTOR Revenue Over Time (2022–2025)
CTOR Revenue Growth History
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- N/A
- FY2025 revenue growth
- N/A
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $1.7M | — |
| Q1 2026 | $3.9M | — |
| Q4 2025 | $0 | — |
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | — |
| Q1 2025 | $0 | — |
| Q4 2024 | $0 | — |
| Q3 2024 | $0 | — |
CTOR Revenue Analysis (2022–2025)
Current Revenue & Growth
As of June 28, 2026, Citius Oncology, Inc. (CTOR) generated trailing twelve-month (TTM) revenue of $5.6 million. The most recent quarter (Q2 2026) recorded $1.7 million in revenue, down 57.7% sequentially.
Historical Growth Trajectory
CTOR's historical revenue data shows various trends over time.
Peer Comparison
Compared to Healthcare sector peers — including HALO (+39.1% YoY), NKTR (-36.2% YoY), and ADMA (+11.0% YoY). Compare CTOR vs HALO →
CTOR Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CTORCurrent | $6M | - | - | - | |
 HALO | $1.4B | +39.1% | +39.2% | 58.4% | |
 NKTR | $55M | -36.2% | -18.4% | -236.8% | |
 ADMA | $510M | +11.0% | +64.6% | 37.5% | |
 TGTX | $616M | +81.3% | +426.7% | 20.0% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% |
CTOR Historical Revenue Data (2022–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $0 | - | $-23,522,750 | - |
| 2024 | $0 | - | $0 | - | $-20,572,747 | - |
| 2023 | $0 | - | $0 | - | $-12,121,241 | - |
| 2022 | $0 | - | $0 | - | $-9,713,198 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
4+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CTOR — Frequently Asked Questions
Quick answers to the most common questions about buying CTOR stock.
Is CTOR's revenue growth accelerating or slowing?
CTOR TTM revenue: $6M. YoY growth: N/A. 5-year CAGR: N/A.
What is CTOR's revenue history from 2022 to 2026?
Citius Oncology, Inc. (CTOR) revenue history spans 2022 to 2026. TTM revenue as of 2026 is $6M, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is CTOR's long-term revenue growth rate (CAGR)?
Citius Oncology, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for CTOR.
Why does CTOR's quarterly revenue fluctuate?
CTOR quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Citius Oncology, Inc.'s revenue data from 2022 to 2026 shows full historical quarterly detail on this page.
How is CTOR's revenue distributed by segment?
CTOR reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does CTOR's revenue compare to industry peers?
Citius Oncology, Inc. (CTOR) with TTM revenue of $6M and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.